Evidence map›Paper›PMID 23680534›Full record

ReviewEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2013

Microneedles for intradermal and transdermal drug delivery.

Tuan-Mazlelaa Tuan-Mahmood, Maelíosa T C McCrudden, Barbara M Torrisi, Emma McAlister, Martin J Garland, Thakur Raghu Raj Singh, Ryan F Donnelly

Abstract readReview
In one paragraph

Review in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Nanozyme-Engineered Probiotic Microneedle Patch for Chronic Diabetic Wound Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. The topical application of SphistinDrug delivery and translational research · 2025
    Article
  18. Review
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tuan-Mazlelaa Tuan-MahmoodSchool of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK; Faculty of Pharmacy, The National University of Malaysia (UKM), Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
Maelíosa T C McCrudden
Barbara M Torrisi
Emma McAlister
Martin J Garland
Thakur Raghu Raj Singh
Ryan F Donnelly

Funding

Biotechnology and Biological Sciences Research Council BB/E020534/1
6 · The paper itself

Abstract

The formidable barrier properties of the uppermost layer of the skin, the stratum corneum, impose significant limitations for successful systemic delivery of broad range of therapeutic molecules particularly macromolecules and genetic material. Microneedle (MN) has been proposed as a strategy to breach the stratum corneum barrier function in order to facilitate effective transport of molecules across the skin. This strategy involves use of micron sized needles fabricated of different materials and geometries to create transient aqueous conduits across the skin. MN, alone or with other enhancing strategies, has been demonstrated to dramatically enhance the skin permeability of numerous therapeutic molecules including biopharmaceuticals either in vitro, ex vivo or in vivo experiments. This suggested the promising use of MN technology for various possible clinical applications such as insulin delivery, transcutaneous immunisations and cutaneous gene delivery. MN has been proved as minimally invasive and painless in human subjects. This review article focuses on recent and future developments for MN technology including the latest type of MN design, challenges and strategies in MNs development as well as potential safety aspects based on comprehensive literature review pertaining to MN studies to date.

Indexed as

Drug Delivery SystemsMicroinjectionsNeedlesAdministration, CutaneousAnimalsDiagnostic ImagingHumansHydrogelsPainPerceptionSkinHydrogelsDrug monitoringHydrogel-formingMicroneedleSafetyTransdermal drug deliveryVaccination

Identifiers

PMID23680534
PMCPMC4119996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.